Loading patent…
AssigneeDaiichi Sankyo Company, Limited
InventorsKyoji Yamaguchi, Hisataka Yasuda, Nobuaki Nakagawa, Nobuyuki Shima, Masahiko Kinosaki, Eisuke Tsuda, Masaaki Goto, Kazuki Yano, Akihiro Tomoyasu, Fumie Kobayashi, Naohiro Washida, Ken Takahashi, Tomonori Morinaga, Kanji Higashio
Estimating the term…
Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided. Processes for producing these proteins, polypeptides, and nucleic acid molecules by genetic engineering are provided. Medicinal compounds are provided which comprise proteins and nucleic acids according to the invention, as well as proteins which bind to OBM, including anti-OBM antibodies. These compounds may be used for the treatment of bone disease.
A method of reducing bone resorption in a patient in need thereof, comprising administering to said patient a therapeutic amount of a monoclonal antibody that binds osteoclastogenesis inhibitory factor-binding molecule (OBM) with a Kd of less than 10−9 M, wherein said therapeutic amount is effective to reduce bone resorption and wherein said OBM consists of the amino acid sequence of SEQ ID NO:
A method of inhibiting osteoclast formation in a patient in need thereof, comprising administering to said patient a therapeutic amount of a monoclonal antibody that binds osteoclastogenesis inhibitory factor-binding molecule (OBM) with a Kd of less than 10−9 M, wherein said therapeutic amount is effective to inhibit osteoclast formation, and wherein said OBM consists of the amino acid sequence of SEQ ID NO:
A method of reducing bone resorption in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a monoclonal antibody that binds osteoclastogenesis inhibitory factor-binding molecule (OBM) with a Kd of less than 10−9 M, wherein said antibody is obtained by the method comprising the steps (i) to (iv):
A method for treating a disease accompanying abnormal bone metabolism comprising administering a therapeutic amount of a monoclonal antibody that binds osteoclastogenesis inhibitory factor-binding molecule (OBM) with a Kd of less than 10−9 M, wherein said therapeutic amount is effective to reduce bone resorption or inhibit osteoclast formation, and wherein said OBM consists of the amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.